Reuters: Regulatory News: UPDATE 1-US approves Mylan's purchase of Strides unit, with conditions

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Free Bestselling eBooks Free national bestsellers for your eReader - Fiction, Nonfiction & more! Join 1.5 million book lovers now. Sign-up in under 10 seconds to get the free daily email. From our sponsors

UPDATE 1-US approves Mylan's purchase of Strides unit, with conditions Sep 26th 2013, 23:02 Thu Sep 26, 2013 7:02pm EDT WASHINGTON, Sept 26 (Reuters) - Generic drugmaker Mylan Inc has won U.S. antitrust approval to buy Agila, a unit of India's Strides Arcolab Ltd, subject to divesting some products, the Federal Trade Commission said on Thursday. India's cabinet approved the deal on Sept. 3. The companies will have to divest assets needed to make 11 generic injectable drugs as a condition of approving the deal, the FTC said. The deal for Agila, which is based in the southern Indian city of Bangalore, was valued at $1.6 billion when it was announced in February. The purchase is expected to help Mylan, one of the world's largest generic drugmakers, double its injectable drugs portfolio. The assets that are to be divested are: anti-arrhythmic heart drug amiodarone hydrochloride; surgical anesthetic etomidate injection; cancer drug fluorouracil; hypertension drug labetalol hydrochloride; detoxifying agent mesna; pediatric cancer drug methotrexate sodium (preservative-free); acetylcysteine injection, used to minimize liver damage following an acetaminophen overdose; fomepizole injection, used to treat some types of accidental poisoning; antiviral herpes drug ganciclovir; last-resort antibiotic meropenem. Assets related to the transplant drug mycophenolate mofetil, which is currently only a branded drug but which is expected to have generic release in the near future, also must be sold. Link this Share this Digg this Email Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions